Datopotamab-deruxtecan is made of a mAb, which is targeted against Trop2 and is linked covalently to a cytotoxic payload topoisomerase I inhibitor by a tumor-specific 4 peptide-based linker which is known to be a derivative of exatecan. Here, TACSTD2 is linked to neoplasm.